Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BXT-102
- Development stage
- Preclinical
- Lead developer
- BioXyTran
- Administration
- Oral
01
Overview
BXT-102 is a preclinical-stage therapeutic candidate being developed by BioXyTran for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH), cirrhosis, and fibrosis. The drug is part of BioXyTran's galectin-antagonist platform, which utilizes complex carbohydrate chemistry to inhibit galectin proteins. Galectins, particularly Galectin-3, are known to play a significant role in the progression of chronic inflammation and fibrogenesis. By blocking these proteins, BXT-102 aims to halt or reverse the accumulation of fibrotic tissue in the liver and improve overall organ function. As of current reports, the asset remains in the preclinical phase of development.
02
Targets
LGALS3 (Galectin-3)SARS-CoV-2 spike
Beyond the preview
Go deeper on BXT-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BXT-102.